Struggling with side effects after cancer treatment?

Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.

Click the orange button to the right to learn more.

End-Stage Multiple Myeloma- Blood Clot (DVT) Prevention

Share Button

“patients with advanced cancer admitted to specialist palliative care units (SPCUs) found that 1 in 3 had deep vein thrombosis and that thromboprophylaxis may have little benefit for late-stage disease.”

Patients with advanced end-stage multiple myeloma undergoing palliative care shouldn’t have to worry about blood clots aka DVT. According to the study linked and excerpted below, they do. Thromboprophylaxis is/are therapies to reduce the occurrence  of thromboses aka blood clots.

Patients with advanced MM probably undergo high-dose chemotherapy regimens proceeding  palliative care. It is pretty-well established that chemotherapy causes blood clots.

According to the article, if the patient has had previous blood clots, if he/she is bed bound or if the patient suffers from “lower limb edema” (swollen calves, ankles, etc.) then they are at a high risk of DVT.

Most importantly, thromboprophylaxic (drugs to prevent DVT), don’t help.

As both a cancer survivor and cancer coach, all I can offer is my experience as someone having had two DVT’s previously. I developed a blood clot in my left leg about two weeks after my first course of VAD induction therapy. I developed a DVT in the other leg a couple of years later.

I took and continue to take Nattokinase and Wobenzyme. Blood clot prevention will be a part of my life for the rest of my life as far as I can tell.

To learn more about DVT’s or cancer caregiving, scroll down the page to post a question or comment. I will reply to you ASAP.

Thank you,

David Emerson

  • MM Survivor
  • MM Coach
  • Director PeopleBeatingCancer

Recommended Reading:

Thromboprophylaxis May Not Benefit Patients With Advanced Cancer in Palliative Care

“An observational study of patients with advanced cancer admitted to specialist palliative care units (SPCUs) found that 1 in 3 had deep vein thrombosis and that thromboprophylaxis may have little benefit for late-stage disease. These findings were recently published in The Lancet Haematology.

Prior to this study, the true prevalence of deep vein thrombosis in patients with advanced cancer was unknown. In addition, though thromboprophylaxis is recommended to prevent thromboembolism in the hospital setting, very few studies have determined whether thromboprophylaxis is effective specifically in patients with advanced cancer.

In this prospective, longitudinal, observational study, a cohort of 343 participants admitted to SPCUs were initially evaluated for several clinical characteristics, history of thromboembolism, and previous blood test results. The researchers then screened patients for deep vein thrombosis during disease progression.

The authors reported that the presence of deep vein thrombosis was predicted by

  • a medical history of deep vein thrombosis (P =.011),
  • having been previously bedbound (P =.003), and
  • lower limb edema (P =.009).

Importantly, neither the use of thromboprophylactic agents, such as anticoagulants and antithromboembolism stockings, nor serum albumin levels were associated with the presence of deep vein thrombosis.

The results also indicated there was no difference in survival for patients with deep vein thrombosis (mean survival [MS] = 30.55 days, SD = 5.65) compared with patients without deep vein thrombosis (MS = 31.38 days, SD = 6.56; P =.432).

The authors concluded that their findings “[challenged] current recommendations for prevention of venous thromboembolism in advanced cancer” and raised additional questions about the timing and usage of thromboprophylaxis in this patient population.


1. White C, Noble SIR, Watson M, et al. Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study [published online February 1, 2019]. Lancet Haematol. doi: 10.1016/S2352-3026(18)30215-1

Leave a Comment: